SEC Form 4 · accession 0001578852-26-000022

PTC THERAPEUTICS, INC. · PTCT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EXEC. VP AND CLO

Period of report

Aug 17, 2026

Accepted (ET)

Aug 19, 2026 · 5:20 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001070081

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Aug 17, 2026	M	2,813	$25.69	A	108,085	D
Common Stock^F2	Aug 17, 2026	S	1,844	$72.39	D	106,241	D
Common Stock^F3	Aug 17, 2026	S	969	$72.90	D	105,272	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$25.69	Aug 17, 2026	M	2,813	D	—	Feb 14, 2034	Common Stock	2,813	16,876	D

F1This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
F2This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $71.72 to $72.67 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.73 to $73.02 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.